Bisphosphonate antiresorptive agent. Prepn: JP Kokai 88 150291; K. A. Jaeggi, L. Wilder, US 4939130 (1988, 1990 both to Ciba-Geigy). Effect on bone metabolism: J. R. Green et al., J. Bone Miner. Res. 9, 745 (1994). Determn in plasma by enzyme inhibition assay: F. Risser et al., J. Pharm. Biomed. Anal. 15, 1877 (1997). Stability-indicating HPLC method: B. Mallikarjuna Rao et al., J. Pharm. Biomed. Anal. 39, 781 (2005). Series of articles on pharmacology and clinical development: Br. J. Clin. Pract. Suppl. 87, 15-22 (1996). Review of clinical experience in metastatic bone disease: D. Santini et al., Expert Opin. Biol. Ther. 6, 1333-1348 (2006); in Paget's disease: G. M. Keating, L. J. Scott, Drugs 67, 793-804 (2007). Clinical trial of once-yearly treatment of osteoporosis: D. M. Black et al., N. Engl. J. Med. 356, 1809 (2007).
Bone resorption inhibitor.
Antiosteoporotic; Antipagetic; Bone Resorption Inhibitor